- Email: [email protected]
The discovery and development of HMG-CoA reductase inhibitors
Atherosclerosis Supplements 5 (2004) 67–80
1567-5688/$ – see front matter doi:10.1016/j.atherosclerosissup.2004.08.026
68
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
69
70
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
71
72
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
73
74
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
75
76
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
77
78
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
79
80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
1567-5688/$ – see front matter doi:10.1016/j.atherosclerosissup.2004.08.026
68
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
69
70
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
71
72
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
73
74
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
75
76
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
77
78
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80
79
80
A. Endo / Atherosclerosis Supplements 5 (2004) 67–80